Novel Therapies for asthma

Advances and Problems

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-¿ are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.

Original languageEnglish
Title of host publicationFrontiers in Medicinal Chemistry
EditorsAtta ur Rahman , Allen B. Reitz, M. Iqbal Choudhary
PublisherBentham Books
Pages668-706
Number of pages39
Volume4
ISBN (Electronic)978-1608052073
Publication statusPublished - 2008

Publication series

NameFrontiers in Medicinal Chemistry
PublisherBentham Books
Number4
ISSN (Electronic)1567-2042

Fingerprint

Asthma
Anti-Inflammatory Agents
Apoptosis
Leukotriene Antagonists
Therapeutics
Antibodies, Monoclonal, Humanized
Lung
DNA Vaccines
T-Lymphocyte Epitopes
Histamine Antagonists
Interleukin-5
Glucocorticoid Receptors
Phagocytes
Cadaver
Chemokines
Granulocytes
Eosinophils
Interleukin-4
Pharmaceutical Preparations
Interleukin-10

Cite this

Walsh, G. M. (2008). Novel Therapies for asthma: Advances and Problems. In A. ur Rahman , A. B. Reitz, & M. I. Choudhary (Eds.), Frontiers in Medicinal Chemistry (Vol. 4, pp. 668-706). (Frontiers in Medicinal Chemistry; No. 4). Bentham Books.

Novel Therapies for asthma : Advances and Problems. / Walsh, Garry M.

Frontiers in Medicinal Chemistry. ed. / Atta ur Rahman ; Allen B. Reitz; M. Iqbal Choudhary. Vol. 4 Bentham Books, 2008. p. 668-706 (Frontiers in Medicinal Chemistry; No. 4).

Research output: Chapter in Book/Report/Conference proceedingChapter

Walsh, GM 2008, Novel Therapies for asthma: Advances and Problems. in A ur Rahman , AB Reitz & MI Choudhary (eds), Frontiers in Medicinal Chemistry. vol. 4, Frontiers in Medicinal Chemistry, no. 4, Bentham Books, pp. 668-706.
Walsh GM. Novel Therapies for asthma: Advances and Problems. In ur Rahman A, Reitz AB, Choudhary MI, editors, Frontiers in Medicinal Chemistry. Vol. 4. Bentham Books. 2008. p. 668-706. (Frontiers in Medicinal Chemistry; 4).
Walsh, Garry M. / Novel Therapies for asthma : Advances and Problems. Frontiers in Medicinal Chemistry. editor / Atta ur Rahman ; Allen B. Reitz ; M. Iqbal Choudhary. Vol. 4 Bentham Books, 2008. pp. 668-706 (Frontiers in Medicinal Chemistry; 4).
@inbook{dae43c594d15416a9a44d218daf47470,
title = "Novel Therapies for asthma: Advances and Problems",
abstract = "It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-¿ are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.",
author = "Walsh, {Garry M}",
year = "2008",
language = "English",
volume = "4",
series = "Frontiers in Medicinal Chemistry",
publisher = "Bentham Books",
number = "4",
pages = "668--706",
editor = "{ur Rahman }, Atta and Reitz, {Allen B.} and Choudhary, {M. Iqbal}",
booktitle = "Frontiers in Medicinal Chemistry",

}

TY - CHAP

T1 - Novel Therapies for asthma

T2 - Advances and Problems

AU - Walsh, Garry M

PY - 2008

Y1 - 2008

N2 - It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-¿ are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.

AB - It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and compliance issues, particularly in children and adolescents. There is therefore much effort being made to develop novel more specific and safer therapy for asthma. Efforts are being made to improve existing drugs together with the use of combination therapy with anti-histamines and leukotriene antagonists. An important area for potential advances in glucocorticoid (GC) development include the elucidation of the crystal structure of the GC receptor ligand-binding domain that may provide vital information in dissociating the anti-inflammatory effects of GCs from unwanted side-effects. Other areas include the development of humanised monoclonal antibodies for asthma therapy including those against IgE, IL-4 and IL-5 together with the inhibition of adhesion pathways and/or chemokines responsible for inflammatory cell accumulation in the asthmatic lung. The potential for immunotherapy using T cell peptide epitopes or DNA-based vaccines and the use of anti-inflammatory cytokines such as IL-10 or IFN-¿ are discussed. Several avenues of research are currently underway in an attempt to define mechanisms by which pro-inflammatory cells such as eosinophils can be safely removed from the asthmatic lung through apoptosis induction and their subsequent ingestion by phagocytes. Novel strategies include elucidation of the intracellular pathways controlling granulocyte apoptosis and the receptor mediated events employed by macrophages and bronchial epithelial cells in the recognition and removal of apoptotic cellular corpses. This paper will provide an overview of both the potential and shortcomings of these diverse approaches to drug development for asthma.

M3 - Chapter

VL - 4

T3 - Frontiers in Medicinal Chemistry

SP - 668

EP - 706

BT - Frontiers in Medicinal Chemistry

A2 - ur Rahman , Atta

A2 - Reitz, Allen B.

A2 - Choudhary, M. Iqbal

PB - Bentham Books

ER -